-
Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor
Irene Davis will not stand for re-election and retires from board effective June 1, 2026, due to personal interests, not disagreement.
-
Teknova Q1 revenue $11.1M (+13% YoY); reaffirms FY 2026 guidance $42-44M
Total revenue $11.1M, up 13% YoY; Clinical Solutions revenue surged 85% to $2.1M.
-
Alpha Teknova reports Q4 and FY2025 revenue growth, provides 2026 guidance of $42-44M
Full year 2025 total revenue $40.5M, up 7% from $37.7M in 2024.
-
Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance
Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).
-
Teknova Q2 revenue $10.3M (+7% YoY); net loss narrows to $3.6M; reaffirms FY25 guidance $39-42M
Q2 2025 revenue of $10.3M, up 7% from $9.6M in Q2 2024.
-
Alpha Teknova shareholders elect Demski and Herzick as Class I directors; auditor ratified
Martha J. Demski elected with 42,901,743 votes for (99.1% of votes cast, excluding broker non-votes).
-
Teknova Q1 revenue up 5% to $9.8M, net loss narrows to $4.6M, guidance reaffirmed
Q1 total revenue $9.8M (+5% YoY); Lab Essentials $8.1M (+12%), Clinical Solutions $1.2M (-32%).
-
Teknova reports FY2024 revenue $37.7M (+3% YoY), guides FY2025 $39-42M, amends credit facility
FY2024 revenue $37.7M (+3% YoY); Q4 revenue $9.3M (+18% YoY). Clinical Solutions Q4 revenue $1.85M (+110% YoY).
-
Teknova Q3 revenue up 17% to $9.6M; net loss $7.6M; guidance reiterates $35-38M
Total revenue $9.6M (+17% YoY); Clinical Solutions up 229% to $2.0M; Lab Essentials flat at $7.2M.
-
Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M
Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.
-
Alpha Teknova raises $15.4M via private placement at $1.24/share; insiders buy 12.2M shares
Sold 12,385,883 common shares at $1.24 each, raising ~$15.4M before expenses.
-
Alpha Teknova reports Q2 2024 rev $9.4-9.6M, reaffirms FY guidance $35-38M
Q2 2024 total revenue $9.4-9.6M, down 17-18% YoY but up 7-9% adjusting for large prior-year order.
-
Alpha Teknova board member Ted Davis retires; board size reduced to 8
Ted Davis retired from the Board on June 26, 2024, citing personal and professional interests.
-
Alpha Teknova stockholders elect directors Grossman, Gunstream, Vos; ratify Grant Thornton
81.03% of shares represented at June 24, 2024 annual meeting.
-
Alpha Teknova Q1 revenue $9.3M (+2% YoY); net loss narrows; reaffirms FY guidance $35-38M
Q1 revenue $9.3M, up 2% YoY; net loss $8.1M ($0.20 loss per share) vs $8.8M loss in Q1 2023.
-
Alpha Teknova appoints Grant Thornton as auditor; EY flagged going concern
Audit committee approved Grant Thornton as independent auditor effective March 26, 2024, replacing Ernst & Young.
-
Alpha Teknova reports FY 2023 revenue $36.7M, down 11%; guides 2024 rev $35-38M; receives covenant waiver from MidCap
FY 2023 revenue $36.7M, down 11% YoY; net loss $36.8M ($1.16 diluted EPS); Adjusted EBITDA -$19.2M.
-
Alpha Teknova cuts 15% of workforce, CCO and CPO depart; option repricing approved
Workforce reduction of ~15% of current employees; annualized cost savings estimated at $6.4M.
-
Teknova Q3 revenue $8.2M, down 24% YoY; net loss $10.2M; raised $22.9M equity, trimmed debt
Q3 revenue $8.2M (-24% YoY); Lab Essentials $7.3M (-23%), Clinical Solutions $0.6M (-35%).
-
Alpha Teknova raises $22.9M in equity and amends credit facility with reduced revenue covenants
Raised $22.9M gross via 1.1M registered-direct shares and 11.3M PIPE shares at $1.85/sh; insiders bought 9.05M shares.
-
Alpha Teknova appoints Martha J. Demski to Board, effective Aug 31, replacing McNamara
Martha J. Demski appointed as Class I Director until 2025 annual meeting.
-
Teknova Q2 revenue $11.5M (+26% seq, -1% YoY); cuts 2023 revenue guidance to $37-40M
Q2 revenue $11.5M, up 26% sequentially but down 1% YoY; net loss $7.2M ($0.25/share).
-
Alpha Teknova director Robert McNamara resigns from Board effective Aug 31, 2023
McNamara cited personal and professional commitments; no disagreement with the Board or Company.
-
Alpha Teknova shareholders elect Class II directors and ratify Ernst & Young as auditor for FY2023
92.61% of outstanding shares (26,108,719) represented at the 2023 Annual Meeting.
-
Teknova Q1 revenue $9.1M, down 18% YoY; net loss $8.8M; reaffirms FY23 guidance
Q1 total revenue $9.1M, up 16% sequentially but down 18% from $11.1M in Q1 2022.
-
Teknova reports FY22 revenue $41.4M (+12% YoY); net loss $47.5M; guides FY23 rev $42-46M
Full year revenue $41.4M, up 12% YoY; Q4 revenue $7.9M, down 22% YoY.
-
Alpha Teknova confirms no exposure to Silicon Valley Bank
Company states it holds no cash deposits or securities at Silicon Valley Bank.
-
Alpha Teknova Q3 revenue up 14% to $10.7M, net loss widens on $16.6M goodwill impairment
Revenue $10.7M (+14% YoY); Lab Essentials $9.47M (+32%).
-
Alpha Teknova reports Q2 2022 revenue of $11.7M, up 41% YoY, updates 2022 outlook to $38-42M
Q2 total revenue reached $11.7 million, a 41% increase from $8.3 million in Q2 2021.
-
Alpha Teknova stockholders elect three Class I directors and ratify EY as auditor
Stockholders elected Ted Davis, Alexander Herzick, and Robert McNamara as Class I directors through 2025.
-
Teknova Q1 revenue $11.1M (+23% YoY); guides FY2022 revenue $45-48M
Q1 2022 revenue $11.1M up 23% YoY; Lab Essentials $6.98M, Clinical Solutions $3.81M, Sample Transport $6K.
-
Alpha Teknova expands credit facility to $57.135M via amended MidCap term loan and revolver
New $57.135M facility comprises $52.135M senior secured term loan and $5M revolver (up from $27M).
-
Teknova FY2021 revenue $36.9M (+18% YoY); net loss $9.8M vs $0.6M income in 2020
FY2021 total revenue $36.9M, up 18% YoY; ex-Sample Transport $35.4M, up 31% YoY.
-
Teknova appoints Ken Gelhaus as CCO and Jennifer Henry as SVP Marketing
Ken Gelhaus appointed CCO effective Nov 15, 2021; base salary $377,500 plus 40% bonus and 85,000 stock option.
-
Teknova Q3 2021 revenue up 5% to $9.4M; net loss of $3.3M vs. prior-year profit
Total revenue $9.4M (+5% YoY); excluding Sample Transport, revenue $9.3M (+26% YoY).
-
Alpha Teknova Q2 2021 revenue up 38% to $8.3M; net loss of $2.3M vs prior-year profit
Total revenue $8.3M, +38% YoY; Lab Essentials revenue $6.5M (+46%), Clinical Solutions $1.6M (+32%).